-
2025-522421-36-00
6
2026-02-27
Acute coronary syndrome
-
2025-521805-41-00
5
2026-02-18
Patients with HER2-positive, locally advanced or metastatic breast can
-
2025-522960-34-00
5
2026-02-09
Established cardiovascular disease
-
2024-515765-34-00
5
2026-02-04
English
First-line extensive-stage small-cell lung cancer (ES-SCLC)
-
2025-522400-24-00
10
2026-01-27
Metastatic urothelial cancer
-
2025-522307-14-00
2
2026-01-19
Melanoma
-
2024-512904-21-00
4
2025-12-10
Migraine
-
2025-523083-21-00
5
2025-12-08
PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor
-
2025-521281-97-00
5
2025-12-02
Non-Small Cell Lung Cancer (NSCLC)
-
2023-508548-23-00
5
2025-11-21
Aetiological treatment of moderate-to-severe allergic rhinitis/rhinoco
-
2024-516652-18-00
5
2025-10-10
Atherosclerotic cardiovascular disease (ASCVD) and obesity or overweig
-
2024-520156-22-00
4
2025-10-08
Metastatic hormone-sensitive prostate cancer
-
2024-517780-24-00
5
2025-09-18
Lung Cancer
-
2024-513663-10-01
3
2025-09-17
Neoplasms
-
2025-521340-37-00
5
2025-07-24
small cell lung cancer
-
2024-517568-48-00
5
2025-07-21
Delayed Graft Function after Kidney Transplantation
-
2024-513111-27-00
5
2025-06-26
Psoriatic Arthritis
-
2024-515764-31-00
10
2025-06-13
Non-small cell lung cancer
-
2024-512302-25-00
5
2025-06-06
Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
-
2024-517422-25-00
5
2025-05-22
Metastatic Castration-resistant Prostate Cancer (mCRPC)
-
2024-513853-66-00
5
2025-02-04
KRAS/NRAS and BRAF Wildtype Recurrent, Unresectable or Metastatic Colo
-
2024-519825-39-00
4
2025-01-30
Locally advanced colon cancer (LACC)
-
2023-508960-31-00
5
2024-12-03
Metastatic HER2-positive breast cancer
-
2023-508191-11-00
5
2024-11-28
Systemic lupus erythematosus (SLE)